Califf’s New Spin On US FDA Staffing: Attrition Rate Is Too Low

 
• By Sarah Karlin-Smith

Commissioner also talks drug shortages, difficulty getting key agency and industry priorities done in new pandemic legislation, and how legal challenges to FDA authority could impact pharma companies desire to develop new medicines.

Front of FDA headquarters
FDA Commissioner Robert Califf discussed a range of regulatory issues at BIO 2023 • Source: Shutterstock/Tada Images

More from US FDA

More from Conferences